Innoveren Scientific (IVRN) 10-K 10 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 18, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Medovex Corp.
Entity Central Index Key	0001591165
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 8,909,513
Entity Common Stock, Shares Outstanding		90,224,860
Trading Symbol	MDVX
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash	$ 47,290	$ 245,026
Accounts receivable	145,757	157,069
Other receivables		86,888
Inventory	131,455	294,714
Prepaid expenses	46,153	204,532
Short-term receivable		150,000
Total Current Assets	370,655	1,138,229
Property and Equipment, net of accumulated depreciation	30,393	87,173
Deposits	2,751	2,751
Total Assets	403,799	1,228,153
Current Liabilities
Interest payable	103,709	69,222
Accounts payable	750,958	196,171
Other payables	37,377
Accounts payable to related parties	91,302	12,319
Accrued payroll	451,207
Accrued liabilities	210,846	64,000
Notes payable, current portion	99,017	132,294
Short-term note payable, net of debt discount	598,119
Dividend payable	57,813
Unearned revenue		1,048
Total Current Liabilities	2,400,348	475,054
Long-Term Liabilities
Notes payable, net of current portion		38,990
Deferred rent	267	688
Total Long-Term Liabilities	267	39,678
Total Liabilities	2,400,615	514,732
Stockholders' (Deficit) Equity
Common stock - $.001 par value: 49,500,000 shares authorized, 24,717,270 and 21,163,013 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	24,717	21,163
Additional paid-in capital	35,812,202	33,509,648
Accumulated deficit	(37,833,744)	(32,817,403)
Total Stockholders' (Deficit) Equity	(1,996,816)	713,421
Total Liabilities and Stockholders' Equity (Deficit)	403,799	1,228,153
Series A Preferred Stock [Member]
Stockholders' (Deficit) Equity
Preferred stock value		13
Series B Preferred Stock [Member]
Stockholders' (Deficit) Equity
Preferred stock value	$ 9

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	49,500,000	49,500,000
Common stock, shares issued	24,717,270	21,163,013
Common stock, shares outstanding	24,717,270	21,163,013
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	12,740
Preferred stock, shares outstanding	0	12,740
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	9,250
Preferred stock, shares outstanding	9,250

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues, net of discount of $9,484 and $52, respectively	$ 818,211	$ 207,344
Cost of Goods Sold	(502,789)	(162,837)
Gross Profit	315,422	44,507
Operating Expenses
General and administrative	3,972,446	4,721,893
Sales & Marketing	808,223	865,377
Research and development	204,690	491,076
Loss on asset disposal	32,865
Depreciation and amortization	23,915	27,100
Total Operating Expenses	5,042,139	6,105,446
Operating Loss	(4,726,717)	(6,060,939)
Other Income		957
Other Expenses
Foreign currency transaction loss	19,727
Interest expense	162,200	395,332
Total Other Expenses	181,927	395,322
Loss from Continuing Operations	(4,908,644)	(6,455,314)
Discontinued Operations
Loss from discontinued operations		1,163
Total Loss from Discontinued Operations		(1,163)
Net Loss	(4,908,644)	(6,456,477)
Deemed dividend on outstanding Series B Preferred Stock	(57,813)
Deemed dividend on adjustment to exercise price on certain warrants	(107,697)
Deemed dividend on beneficial conversion features	(403,719)
Net loss attributable to common shareholders	$ (5,477,873)
Loss per share - Basic and Diluted
Continued Operations	$ (0.23)	$ (0.34)
Discontinued Operations
Net Loss per share	$ (0.23)	$ (0.34)
Weighted average outstanding shares used to compute basic and diluted net loss per share	23,458,305	19,142,795

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Discount allowed	$ 9,484	$ 52

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2016	$ 14,855		$ 25,898,054	$ (26,360,926)	$ (448,017)
Beginning Balance, Shares at Dec. 31, 2016	14,855,181
Issuance of common stock in exchange for board of director fees in January 2017	$ 174		239,826		240,000
Issuance of common stock in exchange for board of director fees in January 2017, Shares	173,912
Issuance of common stock pursuant to a private placement completed in February 2017	$ 1,632		1,207,032		1,208,664
Issuance of common stock pursuant to a private placement completed in February 2017, Shares	1,631,730
Issuance of preferred stock pursuant to a private placement completed in February 2017		$ 13	943,673		943,686
Issuance of preferred stock pursuant to a private placement completed in February 2017, Shares		12,740
Issuance of warrants pursuant to a private placement completed in February 2017			465,709		465,709
Issuance of common stock pursuant to the conversion of a short term note in February 2017	$ 166		145,753		145,919
Issuance of common stock pursuant to the conversion of a short term note in February 2017, Shares	165,865
Issuance of preferred stock pursuant to the conversion of a short term note in February 2017		$ 9	826,865		826,874
Issuance of preferred stock pursuant to the conversion of a short term note in February 2017, Shares		9,399
Issuance of warrants pursuant to the conversion of a short term note in February 2017			177,207		177,207
Issuance of common stock pursuant to warrant cancellations in February 2017	$ 200		207,800		208,000
Issuance of common stock pursuant to warrant cancellations in February 2017, Shares	200,000
Issuance of common stock pursuant to preferred stock conversion in March 2017	$ 415	$ (4)	(411)
Issuance of common stock pursuant to preferred stock conversion in March 2017, Shares	414,663	(4,147)
Issuance of common stock pursuant to preferred stock conversion in April 2017	$ 525	$ (5)	(520)
Issuance of common stock pursuant to preferred stock conversion in April 2017, Shares	525,240	(5,252)
Issuance of common stock pursuant to a private placement completed in July 2017	$ 2,956		2,019,670		2,022,626
Issuance of common stock pursuant to a private placement completed in July 2017, Shares	2,956,043
Issuance of warrants pursuant to a private placement completed in July 2017			446,561		446,561
Issuance of common stock in exchange for board of director Fees in October 2017	$ 115		134,885		135,000
Issuance of common stock in exchange for board of director Fees in October 2017, Shares	115,389
Issuance of common stock in exchange for consulting services in October 2017	$ 75		80,925		81,000
Issuance of common stock in exchange for consulting services in October 2017, Shares	74,990
Issuance of common stock in exchange for consulting services in December 2017	$ 50		33,450		33,500
Issuance of common stock in exchange for consulting services in December 2017, Shares	50,000
Stock based compensation			686,169		686,169
Net loss				(6,456,477)	(6,456,477)
Ending Balance at Dec. 31, 2017	$ 21,163	$ 13	33,509,648	(32,817,403)	713,421
Ending Balance, shares at Dec. 31, 2017	21,163,013	12,740
Issuance of common stock pursuant to a private placement completed in February 2018	$ 770		241,727		242,497
Issuance of common stock pursuant to a private placement completed in February 2018, shares	770,000
Issuance of warrants pursuant to a private placement completed in February 2018			52,003		52,003
Issuance of warrants in connection with short-term debt in March 2018			25,646		25,646
Issuance of common stock pursuant to preferred series A stock conversion in March 2018	$ 1,274	$ (13)	(1,261)
Issuance of common stock pursuant to preferred series A stock conversion in March 2018, shares	1,274,000	(12,740)
Issuance of common stock pursuant to conversion of convertible debt in April 2018	$ 266		100,928		101,194
Issuance of common stock pursuant to conversion of convertible debt in April 2018, shares	266,301
Issuance of preferred series B stock pursuant to a private placement completed in May 2018		$ 8	158,565		158,565
Issuance of preferred series B stock pursuant to a private placement completed in May 2018, shares		8,250
Issuance of warrants pursuant to a private placement completed in May 2018			287,995		287,995
Convertible preferred stock - beneficial conversion feature pursuant to a private placement completed in May 2018			373,432		373,432
Issuance of preferred stock pursuant to conversion of short-term debt in May 2018		$ 1	35,674		35,674
Issuance of preferred stock pursuant to conversion of short-term debt in May 2018, shares		1,000
Issuance of warrants pursuant to conversion of short-term debt in May 2018			34,038		34,038
Convertible preferred stock - beneficial conversion feature pursuant to conversion of short-term debt in May 2018			30,287		30,287
Issuance of warrants in connection with convertible debt in August 2018			192,330		192,330
Issuance of warrants in connection with short-term debt in September 2018			52,246		52,246
Issuance of common stock in exchange for consulting services in October 2018	$ 75		23,925		24,000
Issuance of common stock in exchange for consulting services in October 2018, shares	75,000
Issuance of common stock in exchange for board fees in October 2018	$ 320		179,680		180,000
Issuance of common stock in exchange for board fees in October 2018, shares	320,202
Issuance of common stock pursuant to severance pay to a former office in October 2018	$ 324		135,676		136,000
Issuance of common stock pursuant to severance pay to a former office in October 2018, shares	323,810
Issuance of common stock pursuant to bonus compensation to certain officers and employees in October 2018	$ 525		209,453		209,978
Issuance of common stock pursuant to bonus compensation to certain officers and employees in October 2018, shares	524,944
Adjustment of exercise price of certain warrants			107,697	(107,697)
Stock based compensation			120,326		120,326
Dividend payable			(57,813)		(57,813)
Net loss				(4,908,644)	(4,908,644)
Ending Balance at Dec. 31, 2018	$ 24,717	$ 9	$ 35,812,202	$ (37,833,744)	$ (1,996,816)
Ending Balance, shares at Dec. 31, 2018	24,717,270	9,250

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities
Net loss	$ (4,908,644)	$ (6,456,477)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,915	27,100
Disposal loss	32,865
Amortization of debt discount	118,340	31,773
Debt conversion expense		355,985
Stock based compensation	120,326	683,169
Straight-line rent adjustment	(421)	(491)
Common stock issued for consulting services	24,000	114,500
Common stock issued for bonuses	209,978
Equity-based severance payments	136,000
Equity-based directors fees	180,000
Changes in operating assets and liabilities, net of effects of disposition:
Accounts receivable	11,312	(157,069)
Other receivables	86,888	(86,888)
Prepaid expenses	158,379	229,632
Inventory	163,259	(294,714)
Unearned revenue	(1,048)	1,048
Accounts payable	554,787	(29,554)
Other payables	37,377
Interest payable	34,487
Accounts payable to related parties	78,983	12,319
Accrued payroll	451,207
Accrued liabilities	146,846	(20,800)
Net Cash Used in Operating Activities	(2,341,164)	(5,590,467)
Cash Flows from Investing Activities
Proceeds from disposition of, net assets of Streamline Inc.	150,000
Expenditures for property and equipment		(16,682)
Net Cash (Used in) Provided by Investing Activities	150,000	(16,682)
Cash Flows from Financing Activities
Principal payments under note payable obligation	(171,072)	(127,885)
Proceeds from issuance of common stock and preferred stock, net of offering costs	774,502	3,838,671
Proceeds from issuance of warrants, net of offering costs	610,220	1,248,575
Proceeds from issuance of promissory notes	174,354
Proceeds from issuance of convertible notes	605,424
Net Cash Provided by Financing Activities	1,993,428	4,959,361
Net Decrease in Cash	(197,736)	(647,788)
Cash - Beginning of period	245,026	892,814
Cash - End of period	47,290	245,026
Cash paid for interest	6,020	7,161
Non-cash investing and financing activities
Finance agreement for insurance policy	74,672	69,343
Conversion of note and accrued interest to common stock and preferred stock	101,194	826,874
Conversion of short-term loan to common stock		145,919
Issuance of warrants for conversion of note		177,207
Issuance of common stock for consulting services	24,000	114,500
Common stock issued for board of director fees	180,000	375,000
Common stock issued for bonus compensation	209,978
Common stock issued for severance	136,000
Issuance of common stock for preferred stock conversion		940
Issuance of common stock warrants for placement agent fees		153,688
Issuance of warrants for promissory note	25,646
Dividends accrued	$ 57,813

Organization

Organization	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1 - Organization Description of Business MedoveX Corp. (the “Company” or “MedoveX”), was incorporated in Nevada on July 30, 2013 as SpineZ Corp. (“SpineZ”) and changed its name to MedoveX Corp. on March 20, 2014. MedoveX is the parent company of Debride Inc. (“Debride”), which was incorporated under the laws of the State of Florida on October 1, 2012. The Company is in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company received CE marking in June 2017 for the DenerveX System and it is now commercially available throughout the European Union and several other countries that accept CE marking. The Company’s first sale of the DenerveX System occurred in July 2017. The Company plans to seek approval for the DenerveX System from the Food & Drug Administration (“FDA”) in the United States. In October 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Regenerative Medicine Solutions, LLC (“RMS”), Lung Institute LLC, RMS Lung Institute Management LLC, Cognitive Health Institute Tampa, LLC, RMS Shareholder, LLC and RMS Acquisition Corp. Pursuant to the terms of the Asset Purchase Agreement, the Company shall purchase all of the assets of RMS, Cognitive Health Institute Tampa, LLC, Lung Institute LLC and RMS Lung Institute Management LLC. The Company executed the Asset Purchase Agreement on January 8, 2019. (See Note 13)

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of Presentation And Principles of Consolidation The accompanying consolidated financial statements include the accounts of MedoveX Corp., its wholly-owned subsidiary, Debride, as well as its wholly owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2018 and 2017 consists of funds deposited in checking accounts with commercial banks. Accounts Receivable, Sales Returns, Discounts and Allowances Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The allowance is estimated for trade accounts receivable based on the expected collectability of accounts receivable after considering the Company’s historical collection experience and the length of time an account is outstanding. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. As the Company only commenced sales in July 2017, all outstanding trade receivables were deemed collectable, thus, no allowance for doubtful accounts was recorded at December 31, 2018 and 2017. Inventory Inventories consist of only finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized. Other Payables Other payables include value added tax (VAT) owed to the German tax authority. As a part conducting business in the European Union (“EU”), the Company’s sales transactions are taxed based on the value of the product. At the end of each reporting period, the Company calculates the value of all taxable sales then subtracts the sum of all taxable purchases and the VAT rate is applied to the difference. Leases The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet. Revenue Recognition The Company has adopted the new 5-step revenue recognition process as promulgated by ASC 606, Revenue from Contracts with Customers (Topic 606), the core principle of which necessitates companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. The early adoption of ASC 606 was completed as of September 30, 2017, which was in the first year the Company generated revenue. The early adoption did not have any retrospective effect on prior year. Identify the contract with the customer Medovex has two types of customers: distributors, and individual customers. Distributors: The Company has distribution agreements with distributors located in Italy, Austria, Colombia, Scandinavia, Brazil, Israel, Australia, Turkey, Spain, Switzerland, Chile, Taiwan, Poland, Slovakia, the Czech Republic and the United Kingdom. For each distributor, a standardized distribution agreement is executed and is the definitive contract between the Company and the customer. Each distribution agreement details the pricing, order placement, stocking requirements, terms of payment, and shipping terms under which the DenerveX System will be shipped to the distributor. The distributor places orders for additional product, but all these orders are subject to the terms of the Distribution Agreement. Direct Customers: In Germany, all customers are direct hospitals and individual practitioners. Sales in Germany are solicited by and placed with third party contractors on behalf of Medovex. Medovex has sales agreements with each third party sales representative selling the DenerveX System. Each sales agreement details the price at which the DenerveX System must be sold to the customer. A purchase order from the customer is required before the Company will ship product to the customer. This purchase order contains all the terms and conditions of the sale and is considered the definitive contract for this type of sale. Identify the performance obligation in the contract Distributors, who sell the DenerveX System to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. The Company has no further obligations once the product is shipped. Stocking distributors are obligated to pay the Company the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Since no right of return exists, the product is not considered consigned inventory. For direct sales to hospitals and practitioners in Germany, the obligation is met when the product is shipped. Our direct customers do not have any contractual rights of return or exchange other than for defective product or shipping error. Determine the transaction price DenerveX Kit: The DenerveX kit consists of one Denervex handheld device, one K-Wire, one dilator, one tissue stabilizer, one portal tube and one portal driver. The product is marketed as a disposable, single-use kit which includes all of the components packaged together. The transaction price for the DenerveX Kit is specifically outlined in the standardized distribution agreements for all distributors. The transaction price for the DenerveX Kit is specifically outlined in the standardized sales rep agreements for all sales contractors. Pro-40 Generators: The DenerveX device requires a custom generator for power and cannot be used for any other purpose. For each initial order of the DenerveX Kit, a generator is provided to each customer at no charge. The Company does not recognize any revenue for the no-charge generator units. The units are removed from inventory and recognized as a cost of sales at the time of shipment. Customers may order demo generators, however, the Company charges a set price for these units. Allocate the transaction price In the Company’s case, all of the transaction price is recorded as revenue. Recognize revenue when or as the entity satisfies a performance obligation Revenue recognition occurs at the time product is shipped, FOB shipping, to all customers from the third-party distribution warehouse located in Berlin, Germany. For Medovex, this is considered the point at which the customer gains control of the Denervex device and there are no remaining material performance obligations. If something abnormal were to happen to the product in transit, the matter would be handled with the carrier, however, the sale would remain intact. Research and Development Research and development costs are expensed as incurred. Advertising The Company expenses all sales and marketing costs as incurred. For the years ended December 31, 2018 and 2017, advertising costs were approximately $149,000 and $332,000, respectively. Foreign Currency transactions The Company transacts some of its operating activities in foreign currencies, most notably the Euro. The Company also has certain assets and liabilities denominated in foreign currencies that are translated to US Dollars for reporting purposes as of and for the year ended December 31, 2018. These amounts are immaterial and are included in other income or expense for the years ended December 31, 2018 and 2017. Because of the immaterial effect noted above, we did not present a separate statement of other comprehensive income. Income Taxes The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary. Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation Loss per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 12,108,743 warrants and 557,282 common stock options outstanding were considered anti-dilutive and excluded for the year ended December 31, 2018. 7,402,910 warrants and 1,314,059 common stock options outstanding were considered anti-dilutive and excluded for the year ended December 31, 2017. Discontinued Operations As more fully described in Note 6, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented. Fair Value Measurements The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. The Company uses the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded, adjusted above, or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. Although the Company believes that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain US bank account balances in excess of FDIC insured limits. The Company may also maintain German bank account balances in excess of Germany’s deposit guarantee regulations within the framework of the German Banks’ Compensation Scheme. At December 31, 2018 and 2017, the Company did not have cash deposits that exceeded federally insured deposit limits in the US or Germany. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits. Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company adopted the amendments of ASU 2014-09 effective quarter ended September 30, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	Note 3 – Inventory Inventories consist only of finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Inventories consisted of the following items as of December 31, 2018, and December 31, 2017: December 31, 2018 December 31, 2017 Split Return Electrodes $ — $ 1,868 Denervex device 5,205 111,596 Pro-40 generator 126,250 181,250 Total $ 131,455 $ 294,714

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 - Property and Equipment Property and equipment consists of the following: Useful Life December 31, 2018 December 31, 2017 Furniture and fixtures 5 years $ 52,857 $ 67,777 Computers and software 3 years 12,130 31,738 Leasehold improvements 5 years — 35,676 64,987 135,191 Less accumulated depreciation (34,594 ) (48,018 ) Total $ 30,393 $ 87,173 Depreciation and amortization expense amounted to $23,915 and $27,100 for the years ended December 31, 2018 and 2017, respectively. The Company recognized a disposal loss of $32,865 for the year ended December 31, 2018. The disposal loss was the result of the resignation of Jarrett Gorlin, the Company’s former CEO. Mr. Gorlin’s severance agreement cancelled the current lease agreement and stated all furniture and equipment located at his office would remain in his possession.

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Equity Transactions	Note 5 - Equity Transactions Series B Preferred Stock Preferences Voting Rights Preferred Series B Stock holders have the right to receive notice of any meeting of holders of Common Stock or Series B Preferred Stock and to vote upon any matter submitted to a vote of the holders of Common Stock or Series B Preferred Stock. Each holder of Series B Preferred Stock shall vote on each matter submitted to them with the holders of Common Stock. LIQUIDATION Upon the liquidation, dissolution or winding up of the business of the Company, whether voluntary or involuntary, each holder of Series B Preferred Stock shall be entitled to receive, for each share thereof, out of assets of the Company legally available therefor, a preferential amount in cash equal to the stated value plus all accrued and unpaid dividends. All preferential amounts to be paid to the holders of Series B Preferred Stock in connection with such liquidation, dissolution or winding up shall be paid before the payment or setting apart for payment of any amount for, or the distribution of any assets of the Company’s to the holders of the Company’s Common Stock. Common stock issuance In November 2016, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $240,000, representing their accrued but unpaid directors’ fees as of December 31, 2016. In January 2017, the Company issued an aggregate of 173,912 shares at $1.38 per share, which was the average closing price of the Company’s stock during 2016, to fulfill this obligation. The closing price of the Company’s stock on January 17, 2017, the day the shares were issued, was $1.16 per share. In August 2017, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $135,000, representing their accrued but unpaid directors’ fees as of September 30, 2017. In October 2017, the Company issued an aggregate of 115,389 shares at $1.17 per share, which was the average closing price of the Company’s stock through September 30, 2017, to fulfill this obligation. The closing price of the Company’s stock on October 30, 2017, the day the shares were issued, was $1.09 per share. In August 2017, the Board authorized the issuance of up to 125,000 shares of common stock to a certain member of the Board of Directors and up to 175,000 shares of common stock to a certain consultant. At the inception of the agreement, 25% of the shares were issued to both the director and the consultant. In December 2017, 50,000 shares were issued to the consultant. In October 2018, the board member and consultant were issued an additional 75,000 vested shares. The 75,000 shares were valued at the performance completion date, August 16, 2018, at $0.32 per share, which was the closing price on that date. The Company recognized $24,000 and $115,000, respectively, in consulting expense with respect to the vested stock issuance at December 31, 2018 and 2017. In October 2018, the Board authorized the issuance of shares of common stock to all Board members in an amount equivalent to $180,000, representing their accrued but unpaid directors’ fees as of September 30, 2018. Per Board resolution, the Company issued an aggregate of 320,202 shares at $0.56 per share to settle accrued unpaid director fees. The closing price of the Company’s stock on October 3, 2018, the day the shares were issued, was $0.40 per share. In October 2018, the Board authorized the issuance of shares of common stock to Jarrett Gorlin in an amount equivalent to $136,000, representing 6 months’ severance pay. The Company issued an aggregate of 323,810 shares at $0.42 per share. The closing price of the Company’s stock on October 3, 2018, the day the shares were issued, was $0.40. Stock-Based Compensation Plan 2013 Stock Option Incentive Plan On October 14, 2013, shareholders approved the MedoveX Corp. 2013 Stock Incentive Plan (the “Plan”). Under the Plan, the Company may grant incentive stock options to employees and non-statutory stock options to employees, consultants, and directors for up to 1,150,000 shares of common stock. On November 10, 2016, shareholders approved a 500,000 share increase in the number of shares available for issuance under the Plan, from 1,150,000 to 1,650,000 shares. On October 28, 2017, shareholders approved a 1,000,000 share increase in the number of shares available for issuance under the Plan, from 1,650,000 to 2,650,000 shares. The stock options are exercisable at a price equal to the market value on the date of the grant. The Plan gives full authority for granting options, determining the type of options granted, and determining the fair market value of the options to the Plan Administrator which is the Board of Directors. The Company has the right, but not obligation, to repurchase any shares obtained through exercise of an option from terminated Plan participants. The Company has 90 days from the date of termination to exercise it’s repurchase right. The Company must pay the Fair Market Value (“FMV”) of the shares if the termination was for any reason other than for cause, or the option price (if less than FMV of the shares) if the termination is for cause. The FMV is determined by the Plan Administrator on the date of termination. During 2017, the Company granted options to purchase 189,159 shares of common stock to certain employees. The options vest as follows: 25% on the date of grant and 25% on each of the next three anniversaries. The options granted were at the market value of the common stock on the date of the grant. No stock options were granted in 2018. The Company utilizes the Black-Scholes valuation method to recognize compensation expense over the vesting period. The expected life represents the period that our stock-based compensation awards are expected to be outstanding. The Company uses a simplified method provided in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, No dividend payouts were assumed as the Company has not historically paid, and does not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the weighted average interest rate offered for US treasury rates over the expected term of the options. For the years ended December 31, 2018 and 2017, the Company recognized approximately $120,000 and $683,000, respectively, as compensation expense with respect to stock options. A summary of the Company’s share-based compensation activity and related information is as follows: Shares Weighted Average Exercise Price Weighted Term Outstanding at 12/31/2016 1,124,900 $ 2.15 9.0 Granted 189,159 $ 1.17 9.10 Exercised — — — Cancelled — — — Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Granted — — — Exercised — — — Cancelled (756,777 ) $ 1.44 — Outstanding at 12/31/2018 557,282 $ 2.78 6.99 Exercisable at 12/31/2018 469,179 $ 3.08 6.84 As of December 31, 2018, there were 88,103 shares of unvested stock. Unrecognized compensation cost amounts to approximately $30,000 as of December 31, 2018 and will be recognized as an expense on a straight-line basis over a remaining weighted average service period of 1.28 years. The fair value of vested share-based compensation at December 31, 2018 and 2017 was approximately $188,000 and $544,000, respectively. Private Placements On February 9, 2017, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell in a private placement a minimum of $3,000,000 and up to a maximum of $5,000,000 of units. Each Unit had a purchase price of $100,000 and consisted of (i) 96,154 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.04 per share, and (ii) a warrant to purchase 48,077 shares of common stock. Each warrant has an initial exercise price of $1.50 per share and is exercisable for a period of five (5) years from the date of issuance. Investors had the option to request shares of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) in lieu of common stock, on a basis of one share of preferred stock for every one hundred shares of common stock. The offering resulted in gross proceeds of $3,022,000 and resulted in the issuance of an aggregate of 1,631,730 shares of common stock, 12,740 shares of Series A Preferred Stock and warrants to purchase 2,005,761 shares of common stock. The placement agent collected an aggregate of approximately $350,000 in fees related to the offering and warrants to purchase an aggregate of 405,577 shares of common stock at a price of $1.50 per share. Each share of Series A Preferred Stock may be converted into shares of fully paid and non-assessable shares of common stock at a rate of one hundred shares of the Company’s common stock for every share of Series A Preferred Stock. On July 14, 2017, the Company entered into a Securities Purchase Agreement with selected accredited investors whereby the Company sold an aggregate of 2,956,043 shares of common stock and 1,478,022 warrants to purchase common stock. The Offering resulted in $2,690,686 in gross proceeds to the Company. The placement agent collected $188,000 in total fees related to the offering. The common stock shares were sold at $0.91 per share which was the closing price of the Company’s common stock on July 13, 2017, the day prior to the agreement. Each warrant has an exercise price of $1.15 and is exercisable for a period of five years commencing six months from the date of issuance. On February 26, 2018, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company sold an aggregate of 770,000 shares of common stock and 385,000 warrants to purchase common stock. The offering resulted in $308,000 in gross proceeds to the Company. The warrants have a five-year term commencing six months from issuance with an exercise price of $0.75. The Company allocated $52,003 to the warrants and the remainder to the issuance of the common stock based on each instruments relative fair value. The Company incurred $13,500 in legal expenses related to the offering. On May 1, 2018, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered up to $1,000,000 in units. Each unit had a purchase price of $100,000 and consisted of (i) 1,000 shares of the Company’s 5% Series B Convertible Preferred Stock (the “ Series B Shares The Warrants are exercisable for a period of three (3) years from the date of issuance at an initial exercise price of $0.75 per share subject to downward adjustment if the Company issues any common stock or common stock equivalents at a price less than $0.75 per share while the warrants are outstanding. As a result of the offering, the Company sold an aggregate of 8.25 Units and issued to the Investors an aggregate of 8,250 Series B Shares and 2,062,500 warrants to purchase common stock, resulting in total $825,000 gross proceeds to the Company. The Company incurred $5,000 in legal fees related to the offering, which resulted in $820,000 net cash received from the offering. The 8,250 Series B Shares sold in the Offering are initially convertible into an aggregate of 2,062,500 shares of Common Stock. Of the net proceeds in the offering of $820,000, approximately $288,000 was first allocated to the warrants issued to investors based on their relative fair value. The Company recognized a beneficial conversion feature related to the Series B Shares of approximately $373,000, which was credited to additional paid-in capital, and the residual amount of approximately $159,000 was allocated to the Series B Shares. Because the Series B Shares can immediately be converted by the holder, the discount recognized by the allocation of proceeds to the beneficial conversion feature was immediately accreted and recognized as a dividend to the preferred shareholders. On August 1, 2018 the annual dividend rate on the Series B Shares was adjusted to 12%, which is equal to the same rate as the convertible debt issued in August and September 2018, pursuant to an adjustment provision in the Series B Shares which entitles the holders to receive a more beneficial annual dividend rate offered in any subsequent financings. The Company had accrued unpaid dividends in the amount of approximately $58,000 as of December 31, 2018, related to the Series B Shares. On August 8, 2018, the Company completed the issuance of convertible debt at an initial conversion price of $0.40. Accordingly the exercise price on all of the warrants issued with the Series B Shares were adjusted downward to $0.40. In conjunction with the downward adjustment, the Company recorded a deemed dividend of approximately $108,000 representing the difference in the fair value of the warrants immediately before and after the adjustment to the exercise price. preferred Stock Conversion On March 28, 2017, 4,147 shares of Series A Preferred Stock were converted into an aggregate of 414,663 restricted shares of authorized common stock, par value $0.001 per share. On April 21, 2017, 5,252 shares of Series A Preferred Stock were converted into an aggregate of 525,240 restricted shares of authorized common stock, par value $0.001 per share. On March 30, 2018, 12,740 shares of Series A Preferred Stock were converted into an aggregate of 1,274,000 restricted shares of authorized common stock, par value $0.001 per share. CONVERTIBLE NOTES In August and September 2018, the Company entered into a securities purchase agreement with select accredited investors, whereby the Company offered up to $1,000,000 in units at a purchase price of $50,000 per unit. Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. The notes are secured by all of the assets of the Company. ASU 2017-11, Earnings per share (Topic 260), provided that when determining whether certain financial instruments should be classified as liability or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. If a down round feature on the conversion option embedded in the note is triggered, the Company will evaluate whether a beneficial conversion feature exists, the Company will record the amount as a debt discount and will amortize it over the remaining term of the debt. If the down round feature in the warrants is triggered, the Company will recognize the effect of the down round as a deemed dividend, which will reduce the income available to common stockholders. In the offering, the Company sold an aggregate of 15 units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. If converted at $0.40 the convertible notes sold in the offering are convertible into an aggregate of 1,875,000 shares of common stock. The Company recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of approximately $505,000 and $245,000, respectively. Accretion expense related to the discount on these convertible notes for the year ended December 31, 2018 was approximately $93,000. The Company recognized $33,700 in unpaid accrued interest expense related to the notes as of December 31, 2018. Debt Conversion Short-Term Note Payable On February 9, 2017, the Company’s $1,150,000 short-term note payable was converted into an aggregate of 165,865 shares of common stock and 9,399 shares of Series A Preferred Stock and warrants, eliminating the Company’s debt obligation. The debt was converted into shares at $1.04 per share, which was the offering price of the Company’s stock in the February private placement. Each share of Series A Preferred Stock may be converted into shares of fully paid and non-assessable shares of common stock at a rate of one hundred shares of the Company’s common stock for every share of Series A Preferred Stock. As consideration for converting the debt, the noteholders’ agreed to receive common stock in lieu of the 200,000 warrants to purchase common stock that were issued in conjunction with the short-term loan. As a result, the 200,000 warrants were cancelled, and the Company issued to the noteholders’ an aggregate of 200,000 shares of common stock. The closing price of the Company’s stock on February 9, 2017, the day the shares were issued, was $1.04 per share. The fair value of the common stock issued was approximately $208,000. Convertible Debenture On April 26, 2018, the Company’s $100,000 5% convertible debenture and unpaid accrued interest of $1,194 was converted into an aggregate of 266,301 shares of common stock, eliminating the Company’s debt obligation. The debt was converted into shares at $0.38 per share, which was 85% of the average closing price of the Company’s stock during the twenty trading days immediately preceding the delivery of the notice of conversion. The market value of the common stock on the date of the conversion was $0.40. This difference noted above lead to an immaterial amount related to a beneficial conversion feature. Promissory Note On March 26, 2018 the Company issued a promissory note to Steve Gorlin, father of Jarrett Gorlin, the Company’s former CEO, for the principal amount of $200,000, plus interest, at a rate of five percent per year. The outstanding principal and all accrued but unpaid interest was originally due on May 15, 2018. The Company issued warrants to purchase an aggregate of 133,333 shares of common stock par value $.001 per share in conjunction with the promissory note to Mr. Gorlin. Each warrant has an exercise price of $0.75 and is exercisable for a period of five years commencing from the date of issuance. The balance of the loan was initially recorded net of discount for the warrants of approximately $26,000, based on their relative fair value, which was being accreted to its $200,000 face amount over the period the loan was outstanding. On May 15, 2018, the Company entered into a modification agreement with Steve Gorlin whereby he agreed to convert $100,000 of the $200,000 outstanding promissory note into Series B Preferred Shares. The conversion of $100,000 was converted under the terms of the May 1, 2018 securities purchase agreement. The $100,000 conversion was converted into an aggregate of 1,000 shares of the Company’s Series B Preferred Shares and 250,000 warrants to purchase common stock, eliminating $100,000 of the Company’s $200,000 debt obligation. Of the converted $100,000, approximately $34,000 was first allocated to the fair value of the warrants issued in conjunction with the conversion based on their relative fair value. The Company recognized a beneficial conversion feature related to the Series B Shares of approximately $30,000, which was credited to additional paid-in capital, and the residual amount of approximately $36,000 was allocated to the Series B Shares. Because the Series B Shares can immediately be converted by the holder, the discount recognized by the allocation of proceeds to the beneficial conversion feature was immediately accreted and recognized as a deemed dividend to the preferred shareholders. On August 21, 2018, the Company paid back the remaining $100,000 plus unpaid accrued interest in the amount of $2,944, eliminating the Company’s debt obligation.

Commitments & Contingencies

Commitments & Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 6 – Commitments & Contingencies Operating Leases Office Space Prior to the resignation of Jarrett Gorlin (“Mr. Gorlin”), the Company’s former Chief Executive Officer, the Company paid TAG Aviation (“TAG”), a company owned by Mr. Gorlin, for office space that was being used as the Company’s principal business location plus utilities (see “Related Party Transactions”) on a monthly basis. Base rental payments under the arrangement was $2,147 per month. Rent expense and utilities cost incurred by TAG amounted to approximately $34,555 for the year ended December 31, 2018, of which approximately $6,300 was included in accounts payable at December 31, 2018. Rent expense and utilities cost incurred by TAG amounted to approximately $34,600 for the years ended December 31, 2017. No future lease payments are required under this rental agreement at December 31, 2018. On September 1, 2018, the Company extended the term of the lease agreement for the commercial building which originally commenced on August 1, 2015. The term of the new lease agreement is for two years four months commencing on September 1, 2018 and ending December 31, 2020. Base rent under the old lease agreement was $2,948 and base rent under the new agreement is $3,095. Total lease expense for the year ended December 31, 2018 was approximately $33,000 related to this lease, of which approximately $3,400 was included in accounts payable at December 31, 2018. Total lease expense for the year ended December 31, 2017 was approximately $35,000 related to this lease. Future minimum lease payments under this rental agreement are approximately as follows: For the year ended December 31, 2019 37,510 December 31, 2020 38,635 $ 76,145 Equipment The Company had a non-cancelable 36-month operating lease agreement for equipment that was located at Mr. Gorlin’s office. The equipment remained with Mr. Gorlin after his resignation per the terms of his severance agreement. The Company has no further commitments under this operating lease agreement as of December 31, 2018. Total lease expense for equipment was approximately $2,500 and $2,600, respectively, for the years ended December 31, 2018 and 2017, respectively. Consulting Agreements The Company has a modified agreement with Jesse Crowne, a former Director and Co-Chairman of the Board of the Company, to provide business development consulting services for a fee of $13,333 per month. The Company incurred $160,000 for the year ended December 31, 2018 related to this consulting agreement, of which $40,000 was included in accounts payable at December 31, 2018. The monthly consulting fee was increased from a rate of $9,167 beginning in January 2018. The Company incurred $110,000 for the year ended December 31, 2017, related to this consulting agreement. The Company had a modified consulting agreement with a sales, marketing, and distribution consultant in Latin America at a fee of $7,000 per month through December 31, 2018. The Company terminated the agreement effective November 30, 2018. The Company incurred $77,000 for the year ending December 31, 2018, of which $14,000 was in accounts payable at December 31, 2018. The Company incurred $66,000 for the year ended December 31, 2017 related to this consulting agreement. The Company had consulting agreements with a varying team of sales, marketing, and distribution consultants in Europe who provided consulting services for aggregate compensation amounting to approximately €21,000 (approximately $23,000) per month. The consulting agreements were cancelled by the Company effective November 30, 2018. The Company incurred approximately $263,000 and $238,000, respectively, for the years ended December 31, 2018 and 2017 related to these consulting agreements. Generator development agreement The Company is obligated to reimburse Bovie up to $295,000 for the development of the Pro-40 electrocautery generator. For the year ended December 31, 2018, the Company incurred approximately $19,000 under this agreement, of which $15,000 was included in accounts payable at December 31, 2018. For the year ended December 31, 2017, the Company incurred approximately $33,200 under this agreement. Through December 31, 2018, the Company has incurred approximately $441,000 for production services from Bovie. The original $295,000 agreement was a base number along the pathway of development. Additional requirements were incurred as the research and development process progressed and as a result certain prices increased and additional costs were incurred to further customize the DenerveX System. We are currently in production manufacturing of the generator. Distribution center and logistic services agreement The Company has a non-exclusive distribution center agreement with a logistics service provider in Berlin, Germany pursuant to which they manage and coordinate the DenerveX System products which the Company exports to the EU through June 2019. The Company originally paid a fixed monthly fee of €2,900 (approximately $3,500) for all accounting, customs declarations and office support, and a variable monthly fee ranging from €1,900 to €6,900 (approximately $2,300 to $8,300), based off volume of shipments, for logistics, warehousing and customer support services. Effective September 1, 2018, the fixed monthly fee was changed to €6,900 (approximately $7,900). Total expenses paid for the distribution center and logistics agreement was approximately $142,000 for the year ended December 31, 2018, of which approximately $16,000 was included in accounts payable at December 31, 2018. Total expenses paid for the distribution center and logistics agreement was approximately $75,700 for the year ended December 21, 2017. Co-Development Agreement In September 2013, the Company executed a Co-Development Agreement with James R. Andrews, M.D. (“Dr. Andrews”) to further evaluate, test and advise on the development of products incorporating the use of the patented technology. In exchange for these services the Company was obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews was listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would have continued to receive a 1% royalty after the 2% royalty expired for the duration of the effectiveness of the Improvement Patent. The co-development agreement expired September 30, 2018. The Company incurred approximately $13,000 in royalty expense under the co-development agreement for the year ended December 31, 2018, all of which is in accounts payable at December 31, 2018. The Company incurred approximately $1,000 in royalty expense under the co-development agreement for the year ended December 31, 2017, all of which was included in accounts payable at December 2017 and subsequently paid in 2018. Patent Assignment and Contribution Agreements On February 1, 2013, the Company issued 750,108 shares of common stock to Scott Haufe, M.D. (“Dr. Haufe”) pursuant to the terms of a Contribution and Royalty Agreement dated January 31, 2013 between the Company and Dr. Haufe. This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030. The Company incurred approximately $8,700 in royalty expense under the Contribution and Royalty agreement for the year ended December 21, 2018, all of which is included in accounts payable at December 31, 2018. The Company incurred approximately $800 in royalty expense under the Contribution and Royalty agreement for the year ended December 21, 2017, all of which was included in accounts payable at December 31, 2017 and subsequently paid in 2018. Streamline Inc. Asset Sale The asset sale of Streamline Inc. resulted in the immediate receipt of $500,000 in cash in December 2016, and a $150,000 note receivable that was due to the Company on January 1, 2018. The $150,000 note receivable represents the non-contingent portion of the receivables due from the sale. The Company received the short-term receivable on January 2, 2018. The terms of the sale also required that for each of the calendar years ending December 31, 2018 and December 31, 2019 (each such calendar year, a “Contingent Period”), a contingent payment in cash (each, a “Contingent Payment”) equal to five percent (5%) of the total net sales received by the acquiring party from the sale of “IV suspension system” products in excess of 100 units during each Contingent Period. Each such Contingent Payment is payable to the Company by the acquiring party by no later than March 31st of the subsequent year; provided, however, that the total aggregate amount of all Contingent Payments owed by the acquiring party to the Company for all Contingent Periods will not exceed $850,000. The Company is yet to receive any Contingent Payments and has no reason to expect it will receive any Contingent Payments. The Company did not incur any Streamline related expenses for the year ended December 31, 2018. The Company recorded a nominal amount in Streamline related expenses for the year ended December 31, 2017.

Short Term Liabilities

Short Term Liabilities	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Short Term Liabilities	Note 7 – Short Term Liabilities Finance Agreement The Company entered into a commercial insurance premium finance and security agreement in December 2017. The agreement finances the Company’s annual D&O insurance premium. Payments are due in quarterly installments of approximately $24,000 and carry an annual percentage interest rate of 5.98%. The Company had paid the yearly premium in full and had no outstanding balance as of December 31, 2018 related to the agreement. Promissory Notes In conjunction with the consummation of the Streamline acquisition in March 2015, the Company assumed two promissory notes for approximately $135,000 and $125,000 payable to the Bank of North Dakota New Venture Capital Program and North Dakota Development Fund, both outside non-related parties. Assumption of the liabilities was not included as part of the asset purchase agreement that was executed in December 2016. Thus, the Company retained the promissory notes upon consummation of the divestiture. Payments on both of the notes are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. Both of the notes have a maturity date of August 1, 2019. The promissory notes had outstanding balances of approximately $103,000 and $104,000 at December 31, 2018 and December 31, 2017, respectively. The Company incurred interest expense related to the notes for the years ended December 31, 2018 and 2017 in the amount of approximately $3,400 and $7,000, respectively. The Company had unpaid accrued interest in the amount of approximately $70,000 and $69,000 at December 31, 2018 and 2017, respectively, related to the notes. Expected future payments related to the promissory notes as of December 31, 2018, are approximately as follows: For the year ended 2019 103,000 $ 103,000 Convertible Debenture On January 31, 2018, the Company issued a 5% convertible debenture in exchange for $100,000. The debenture accrued interest at 5% per annum. Principal and interest were due on January 30, 2019. The debenture was convertible at the option of the holder into shares of the Company’s common stock at a conversion rate equivalent to 85% of the average closing price of the Company’s common stock for the 20 days preceding the conversion. On April 26, 2018, the convertible debenture and unpaid accrued interest was converted into an aggregate of 266,301 shares of common stock, eliminating the Company’s debt obligation (Note 5). Prior to the conversion, the Company recognized approximately $1,200 in interest expense related to the convertible debenture during the year ended December 31. 2018. The market value of the common stock on the date of the conversion was $0.40. This difference lead to an immaterial amount related to a beneficial conversion feature. Convertible Notes In August and September 2018, the Company entered into a securities purchase agreement with select accredited investors, whereby the Company offered up to $1,000,000 in units at a purchase price of $50,000 per unit. Each unit consists of a 12% senior secured convertible note and a three-year warrant to purchase shares of the Company’s common stock. The notes are secured by all of the assets of the Company. (See Note 5). In the offering, the Company sold an aggregate of 15 units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. The convertible notes sold in the offering are initially convertible into an aggregate of 1,875,000 shares of common stock but could convert into additional shares if the Company completes a down round financing during the term of the convertible notes. The Company recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of $505,424 and $244,576, respectively. Accretion expense related to the discount on these convertible notes for the year ended December 31, 2018 was approximately $93,000. The Company recognized $33,700 in unpaid accrued interest expense related to the notes as of December 31, 2018.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Common Stock Warrants	Note 8 – Common Stock Warrants Fair value measurement valuation techniques, to the extent possible, should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company’s fair value measurements of all warrants are designated as Level 1 since all of the significant inputs are observable and quoted prices used for volatility were available in an active market. A summary of the Company’s warrant issuance activity and related information as of December 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2016 3,713,542 $ 2.19 3.8 Issued 3,889,368 $ 1.37 4.3 Cancelled (200,000 ) $ 1.625 — Outstanding at 12/31/2017 7,402,910 $ 1.77 3.5 Issued 4,705,833 (1)(2) 2.7 Outstanding at 12/31/2018 12,108,743 $ 1.38 2.6 Exercisable at 12/31/2018 12,108,743 $ 1.38 2.6 The fair value of all warrants issued are determined by using the Black-Scholes-Merton valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued in 2018 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 2/26/18 $ 0.51 $ 0.75 $ 0.20 5 years 2.60 55.91 Short-term debt 3/26/18 $ 0.53 $ 0.75 $ 0.22 5 years 2.64 56.57 Private placement 5/1/2018 $ 0.44 (1 ) $ 0.24 3 years 2.66 103.29 Debt conversion 5/15/2018 $ 0.39 (1 ) $ 0.20 3 years 2.75 103.32 Convertible notes 8/8/2018 $ 0.37 (2 ) $ 0.19 3 years 2.68 104.37 Convertible notes 9/28/2018 $ 0.40 (2 ) $ 0.21 3 years 2.88 105.07 (1) (2) The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 - Income Taxes The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. As of December 31, 2018, the Company has not incurred any interest or penalties relating to uncertain tax positions. The Company’s evaluation was performed for the tax years ending December 31, 2017, 2016 and 2015, which remain subject to examination by major tax jurisdictions as of December 31, 2018. The Company’s tax year ending in December 31, 2014 is no longer subject to U.S. federal, state, and local, or non-US income tax examinations. For the years ended December 31, 2018 and 2017, the Company has incurred net losses and, therefore, has no current income tax liability and recognized no income tax expense. The net deferred tax asset generated by these losses, which principally consist of start-up costs deferred for income tax purposes, is fully reserved as of December 31, 2018 and 2017 since it is more likely than not that the benefit will not be realized in future periods. A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows: 2018 2017 Statutory rate – federal 21.0 % 21.0 % State taxes, net of federal benefit 4.0 4.0 Income tax benefit 25.0 % 25.0 % Less valuation allowance (25.0 ) (25.0 ) Total 0.00 % 0.00 % The Company’s financial statements contain certain deferred tax assets which have arisen primarily as a result of losses incurred that are considered startup costs for tax purposes, as well as net deferred income tax assets resulting from other temporary differences related to certain reserves and differences between book and tax depreciation and amortization. We record a valuation allowance against our net deferred tax assets when we determine that based on the weight of available evidence, it is more likely than not that our net deferred tax assets will not be realized. In our evaluation of the weight of available evidence, the Company considered recent reported losses as negative evidence which carried substantial weight. Therefore, the Company considered evidence related to the four sources of taxable income, to determine whether such positive evidence outweighed the negative evidence associated with the losses incurred. The positive evidence considered included: ● taxable income in prior carryback years, if carryback is permitted under the tax law; ● future reversals of existing taxable temporary differences; ● tax planning strategies; and ● future taxable income exclusive of reversing temporary differences and carryforwards. During fiscal 2018 and 2017, the Company weighed all available positive and negative evidence and concluded the weight of the negative evidence of a cumulative loss continued to outweigh the positive evidence. Based on the conclusions reached, the Company maintained a full valuation allowance during 2018 and 2017. Deferred tax assets and liabilities consist of the following at December 31: 2018 2017 Deferred Tax Assets: Start-up costs $ 6,816,896 $ 5,566,520 Share-based compensation 243,848 238,109 Total Deferred Tax Assets 7,060,744 5,804,629 Valuation Allowance (7,060,744 ) (5,804,629 ) Net Deferred Tax Asset $ — $ — The Company is required to file federal income tax returns and state income tax returns in the states of Florida, Georgia and Minnesota. There are no uncertain tax positions at December 31, 2018. The Company has not undergone any tax examinations since inception and is therefore not subject to examination by any applicable tax authorities.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related-Party Transactions	Note 10 - Related-Party Transactions Patent Assignment and Royalty Agreements As described in Note 6, the Company has a Contribution and Royalty Agreement with Dr. Haufe, a former director of the Company. Co-Development Agreement As described in Note 6, the Company entered into a Co-Development Agreement with Dr. Andrews, a former director of the Company. Operating Lease As described in Note 6, the Company paid TAG, a company owned by Mr. Gorlin, for month to month rental of office space at Dekalb-Peachtree Airport in Atlanta Georgia plus cost of utilities. Rent payments under this arrangement were $2,147 per month. Rent expense and utilities cost incurred by TAG amounted to approximately $35,000 for the year ended December 31, 2018, of which approximately $6,300 was included in accounts payable at December 31, 2018. Rent expense and utilities cost incurred by TAG amounted to approximately $34,600 for the years ended December 31, 2017. No future lease payments are required under this rental agreement at December 31, 2018. Consulting Expense As described in Note 6, the Company paid $160,000 and $110,000, respectively, for the years ended December 31, 2018 and 2017, respectively, to Jesse Crowne, a former director and Co-Chairman of the Board of the Company, for business advisory services, of which $40,000 was included in accounts payable at December 31, 2018.

Research and Development

Research and Development	12 Months Ended
	Dec. 31, 2018
Research and Development [Abstract]
Research and Development	Note 11 - Research and Development Devicix Prototype Manufacturing Agreement In November 2013, the Company accepted a proposal from Devicix, a Minneapolis Minnesota based FDA registered contract medical device designer and developer, to develop a commercially viable prototype of its product that could be used to receive regulatory approval from the FDA and other international agencies for use on humans to relieve pain associated with Facet Joint Syndrome. During 2018, the Company incurred approximately $101,000 of expense under this agreement, with approximately $69,000 of the amount in payables at December 31, 2018. During 2017, the Company incurred approximately $302,000 of expense under this agreement, with approximately $7,000 of the amount in payables at December 31, 2017 which was subsequently paid in 2018. DenerveX Generator Manufacturing Agreement The DenerveX device requires a custom electrocautery generator for power. As described in Note 7, in November 2014, the Company contracted with Bovie to customize one of their existing electrocautery generators for use with DenerveX Device, and then manufacture that unit on a commercial basis once regulatory approval for the DenerveX was obtained. The Bovie agreement required a base $295,000 development fee to customize the unit, plus additional amounts if further customization was deemed necessary beyond predetermined estimates. The Company incurred approximately $19,000 for the year ended December 31, 2018, of which $15,000 was included in accounts payable at December 31, 2018. The Company incurred approximately $33,000 for the year ended December 31, 2017. The manufacturing agreement is complete as of December 31, 2018, and the Company does not expect to incur any more expenses related to the agreement. Nortech Manufacturing Agreement In November 2014, the Company selected Nortech Systems Inc. (“Nortech”), a Minneapolis, Minnesota based FDA registered contract manufacturer, to produce 315 DenerveX devices from the prototype supplied by Devicix for use in final development and clinical trials. The agreement with Nortech includes agreed upon per unit prices for delivery of the devices. Actual work on development of the final units began in November 2014. The Company incurred fees of approximately $106,000 to Nortech for the year ended December 31, 2018. The Company incurred fees of approximately $146,000 to Nortech for the year ended December 31, 2017, of which $40,000 was in accounts payable at December 31, 2017.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 12 – Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $4,909,000 and $6,456,000 for the years ended December 31, 2018 and 2017, respectively. The Company will continue to incur losses until such time as it can sell a sufficient enough volume of the DenerveX System with margins sufficient to offset expenses. To date, the Company’s primary source of funds has been from the issuance of debt and equity. The Company anticipates cash expenditures will remain consistent as diminishing research and development costs will be offset by the cost of clinical trials to obtain FDA approval and moving forward with the recent commercialization of the DenerveX System. The Company expects future cash flow expenditures to increase if the FDA requires a de novo regulatory path, instead of a 510(k) approval. The Company also continues to incur similar costs as it continues to operate as a publicly traded entity. Subsequent to year-end, on January 8, 2019, the Company executed the Asset Purchase Agreement with RMS, as amended, by which the Company entered into a securities purchase agreement (the “SPA”) with select accredited investors and raised an aggregate amount of $2,000,000, with $1,800,000 received in cash and $200,000 by cancellation of debt. Subsequent to the consummation of the Asset Purchase Agreement with RMS, the Company has raised an additional $5,200,000 with select accredited investors under the same SPA. Through March 31, 2019 the Company has raised an aggregate of $7,200,000 in convertible note financings. The financial statements do not include any adjustments to the carrying amounts of its assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 13 - Subsequent Events As previously disclosed on a Form 8-K filed on October 18, 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Regenerative Medicine Solutions, LLC (“RMS”), Lung Institute LLC (“Lung Institute”), RMS Lung Institute Management LLC (“RMS Management”), Cognitive Health Institute Tampa, LLC (“CHIT”), RMS Shareholder, LLC (“RMS Shareholder”) and RMS Acquisition Corp. (“RMS Acquisition”) (collectively, the “Parties”). On January 8, 2019, the Parties to the Asset Purchase Agreement entered into an amendment thereto (the “APA Amendment”) to, among other things, i) update the contracts assigned to and liabilities assumed by RMS Acquisition, ii) amend the number of Series C preferred stock of the Company (the “Series C Preferred Stock”) issued to RMS Shareholder from 30,119 shares to 39,772 shares, iii) revise the lists of material contracts, real estate leases, legal proceedings, employees of RMS Management and Lung Institute Tampa, iv) state that the Company shall enter into an employment agreement with James St. Louis, v) include two additional members, Michael Yurkowsky and Raymond Monteleone, to the board of directors of the Company (the “Board”), and vi) revise the patient treatment arrangement among the Parties after closing of the Asset Purchase Agreement. In connection with the Asset Purchase Agreement and APA Amendment, on January 8, 2019, RMS, Lung Institute, RMS Management, CHIT and RMS Acquisition executed an assignment and assumption agreement (the “Assignment and Assumption Agreement”), pursuant to which RMS, Lung Institute, RMS Management and CHIT assigned and transferred to RMS Acquisition all the rights and interests in the Assigned Contracts as listed in the APA Amendment and RMS Acquisition assumed all the obligations and liabilities under the Assumed Liabilities as defined in the APA Amendment. On January 8, 2019, the Company executed the Asset Purchase Agreement, as amended, by which the Company entered into a securities purchase agreement (the “SPA”) with four purchasers (the “Purchasers”) pursuant to which the four Purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt as explained below, in exchange for forty (40) units (the “Units”), each consisting of a convertible note (the “Convertible Note”) with the principal amount of $50,000 and a warrant (the “Warrant”) to purchase common stock (the “Common Stock”) of the Company. Pursuant to this SPA, the Company initially offered a minimum of $1,000,000 and a maximum of $6,000,000, and subsequently increased to a maximum of $8,000,000 (the “Maximum Amount”) of Units at a price of $50,000 per Unit until the earlier of i) the closing of the subscription of the Maximum Amount and ii) March 31, 2019 (the “Termination Date”), subject to the Company’s earlier termination at its discretion. The SPA includes the customary representations and warranties from the Company and purchasers. Steve Gorlin, the Company’s former Chairman of the Board, converted a $200,000 promissory note owed to him by the Company in exchange for four (4) Units on the same terms as all other Purchasers. Each Convertible Note offered by the Company as part of the Unit bears an interest rate of 12% per annum, has a principal amount of $50,000, shall mature in one year from the original issue date on January 8, 2019, and will be convertible into shares of Common Stock at a price of $0.40 subject to adjustment stated in the Convertible Note. Pursuant to the terms of the Convertible Note, each holder of the Convertible Notes shall not own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock issuable upon exercise of such Convertible Note. Upon default, the penalty interest rate of the Convertible Note shall rise to 18% per annum. In addition, pursuant to the SPA, the Company offers, as part of the Unit, Warrants to purchase the Common Stock at a price of $0.75 per share (the “Exercise Price”), subject to adjustments stated therein. The holder of each Warrant may purchase the number of shares of Common Stock equal to the number of shares of Common Stock issuable upon conversion of each Convertible Note while the Warrant is exercisable. The Warrants have a term of three years and shall be exercised in cash or on a cashless basis as described in the Warrant. In March 2018, the Company issued RMS the 39,772,498 shares of Common Stock upon the Conversion of the 39,772 shares of Series C Preferred Stock. The Company also issued RMS an additional 11,152,778 shares of Common Stock to RMS to compensate it for the additional dilution occurred in the recent financing. Through March 31, 2019, the Company has entered into other SPA’s under the same terms with additional purchasers, which has brought the aggregate principal amount of capital raised in the offerings to $7,200,000, as of that date.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation And Principles of Consolidation The accompanying consolidated financial statements include the accounts of MedoveX Corp., its wholly-owned subsidiary, Debride, as well as its wholly owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates.
Cash	Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2018 and 2017 consists of funds deposited in checking accounts with commercial banks.
Accounts Receivable, Sales Returns, Discounts and Allowances	Accounts Receivable, Sales Returns, Discounts and Allowances Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The allowance is estimated for trade accounts receivable based on the expected collectability of accounts receivable after considering the Company’s historical collection experience and the length of time an account is outstanding. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. As the Company only commenced sales in July 2017, all outstanding trade receivables were deemed collectable, thus, no allowance for doubtful accounts was recorded at December 31, 2018 and 2017.
Inventory	Inventory Inventories consist of only finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized.
Other Payables	Other Payables Other payables include value added tax (VAT) owed to the German tax authority. As a part conducting business in the European Union (“EU”), the Company’s sales transactions are taxed based on the value of the product. At the end of each reporting period, the Company calculates the value of all taxable sales then subtracts the sum of all taxable purchases and the VAT rate is applied to the difference.
Leases	Leases The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet.
Revenue Recognition	Revenue Recognition The Company has adopted the new 5-step revenue recognition process as promulgated by ASC 606, Revenue from Contracts with Customers (Topic 606), the core principle of which necessitates companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. The early adoption of ASC 606 was completed as of September 30, 2017, which was in the first year the Company generated revenue. The early adoption did not have any retrospective effect on prior year. Identify the contract with the customer Medovex has two types of customers: distributors, and individual customers. Distributors: The Company has distribution agreements with distributors located in Italy, Austria, Colombia, Scandinavia, Brazil, Israel, Australia, Turkey, Spain, Switzerland, Chile, Taiwan, Poland, Slovakia, the Czech Republic and the United Kingdom. For each distributor, a standardized distribution agreement is executed and is the definitive contract between the Company and the customer. Each distribution agreement details the pricing, order placement, stocking requirements, terms of payment, and shipping terms under which the DenerveX System will be shipped to the distributor. The distributor places orders for additional product, but all these orders are subject to the terms of the Distribution Agreement. Direct Customers: In Germany, all customers are direct hospitals and individual practitioners. Sales in Germany are solicited by and placed with third party contractors on behalf of Medovex. Medovex has sales agreements with each third party sales representative selling the DenerveX System. Each sales agreement details the price at which the DenerveX System must be sold to the customer. A purchase order from the customer is required before the Company will ship product to the customer. This purchase order contains all the terms and conditions of the sale and is considered the definitive contract for this type of sale. Identify the performance obligation in the contract Distributors, who sell the DenerveX System to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. The Company has no further obligations once the product is shipped. Stocking distributors are obligated to pay the Company the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Since no right of return exists, the product is not considered consigned inventory. For direct sales to hospitals and practitioners in Germany, the obligation is met when the product is shipped. Our direct customers do not have any contractual rights of return or exchange other than for defective product or shipping error. Determine the transaction price DenerveX Kit: The DenerveX kit consists of one Denervex handheld device, one K-Wire, one dilator, one tissue stabilizer, one portal tube and one portal driver. The product is marketed as a disposable, single-use kit which includes all of the components packaged together. The transaction price for the DenerveX Kit is specifically outlined in the standardized distribution agreements for all distributors. The transaction price for the DenerveX Kit is specifically outlined in the standardized sales rep agreements for all sales contractors. Pro-40 Generators: The DenerveX device requires a custom generator for power and cannot be used for any other purpose. For each initial order of the DenerveX Kit, a generator is provided to each customer at no charge. The Company does not recognize any revenue for the no-charge generator units. The units are removed from inventory and recognized as a cost of sales at the time of shipment. Customers may order demo generators, however, the Company charges a set price for these units. Allocate the transaction price In the Company’s case, all of the transaction price is recorded as revenue. Recognize revenue when or as the entity satisfies a performance obligation Revenue recognition occurs at the time product is shipped, FOB shipping, to all customers from the third-party distribution warehouse located in Berlin, Germany. For Medovex, this is considered the point at which the customer gains control of the Denervex device and there are no remaining material performance obligations. If something abnormal were to happen to the product in transit, the matter would be handled with the carrier, however, the sale would remain intact.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Advertising	Advertising The Company expenses all sales and marketing costs as incurred. For the years ended December 31, 2018 and 2017, advertising costs were approximately $149,000 and $332,000, respectively.
Foreign Currency Transactions	Foreign Currency transactions The Company transacts some of its operating activities in foreign currencies, most notably the Euro. The Company also has certain assets and liabilities denominated in foreign currencies that are translated to US Dollars for reporting purposes as of and for the year ended December 31, 2018. These amounts are immaterial and are included in other income or expense for the years ended December 31, 2018 and 2017. Because of the immaterial effect noted above, we did not present a separate statement of other comprehensive income.
Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary.
Stock-Based Compensation	Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation
Loss Per Share	Loss per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 12,108,743 warrants and 557,282 common stock options outstanding were considered anti-dilutive and excluded for the year ended December 31, 2018. 7,402,910 warrants and 1,314,059 common stock options outstanding were considered anti-dilutive and excluded for the year ended December 31, 2017.
Discontinued Operations	Discontinued Operations As more fully described in Note 6, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented.
Fair Value Measurements	Fair Value Measurements The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. The Company uses the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded, adjusted above, or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. Although the Company believes that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Goodwill and Impairment of Long-lived Assets	Goodwill And Impairment of Long-Lived Assets Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. Other intangible assets include trademarks and purchased technology. Intangible assets with a definite life are amortized on a straight-line basis, as appropriate, with estimated useful lives ranging from five to seven years, and are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Definite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain US bank account balances in excess of FDIC insured limits. The Company may also maintain German bank account balances in excess of Germany’s deposit guarantee regulations within the framework of the German Banks’ Compensation Scheme. At December 31, 2018 and 2017, the Company did not have cash deposits that exceeded federally insured deposit limits in the US or Germany. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company adopted the amendments of ASU 2014-09 effective quarter ended September 30, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consisted of the following items as of December 31, 2018, and December 31, 2017: December 31, 2018 December 31, 2017 Split Return Electrodes $ — $ 1,868 Denervex device 5,205 111,596 Pro-40 generator 126,250 181,250 Total $ 131,455 $ 294,714

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following: Useful Life December 31, 2018 December 31, 2017 Furniture and fixtures 5 years $ 52,857 $ 67,777 Computers and software 3 years 12,130 31,738 Leasehold improvements 5 years — 35,676 64,987 135,191 Less accumulated depreciation (34,594 ) (48,018 ) Total $ 30,393 $ 87,173

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Nonmonetary Transactions [Abstract]
Summary of Share-based Compensation Activity	A summary of the Company’s share-based compensation activity and related information is as follows: Shares Weighted Average Exercise Price Weighted Term Outstanding at 12/31/2016 1,124,900 $ 2.15 9.0 Granted 189,159 $ 1.17 9.10 Exercised — — — Cancelled — — — Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Granted — — — Exercised — — — Cancelled (756,777 ) $ 1.44 — Outstanding at 12/31/2018 557,282 $ 2.78 6.99 Exercisable at 12/31/2018 469,179 $ 3.08 6.84

Commitments & Contingencies (Ta

Commitments & Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Leases	Future minimum lease payments under this rental agreement are approximately as follows: For the year ended December 31, 2019 37,510 December 31, 2020 38,635 $ 76,145

Short Term Liabilities (Tables)

Short Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Future Payments Related to the Promissory Notes	Expected future payments related to the promissory notes as of December 31, 2018, are approximately as follows: For the year ended 2019 103,000 $ 103,000

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information as of December 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2016 3,713,542 $ 2.19 3.8 Issued 3,889,368 $ 1.37 4.3 Cancelled (200,000 ) $ 1.625 — Outstanding at 12/31/2017 7,402,910 $ 1.77 3.5 Issued 4,705,833 (1)(2) 2.7 Outstanding at 12/31/2018 12,108,743 $ 1.38 2.6 Exercisable at 12/31/2018 12,108,743 $ 1.38 2.6
Schedule of Assumptions for Warrants	The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued in 2018 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 2/26/18 $ 0.51 $ 0.75 $ 0.20 5 years 2.60 55.91 Short-term debt 3/26/18 $ 0.53 $ 0.75 $ 0.22 5 years 2.64 56.57 Private placement 5/1/2018 $ 0.44 (1 ) $ 0.24 3 years 2.66 103.29 Debt conversion 5/15/2018 $ 0.39 (1 ) $ 0.20 3 years 2.75 103.32 Convertible notes 8/8/2018 $ 0.37 (2 ) $ 0.19 3 years 2.68 104.37 Convertible notes 9/28/2018 $ 0.40 (2 ) $ 0.21 3 years 2.88 105.07 (1) (2)

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows: 2018 2017 Statutory rate – federal 21.0 % 21.0 % State taxes, net of federal benefit 4.0 4.0 Income tax benefit 25.0 % 25.0 % Less valuation allowance (25.0 ) (25.0 ) Total 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following at December 31: 2018 2017 Deferred Tax Assets: Start-up costs $ 6,816,896 $ 5,566,520 Share-based compensation 243,848 238,109 Total Deferred Tax Assets 7,060,744 5,804,629 Valuation Allowance (7,060,744 ) (5,804,629 ) Net Deferred Tax Asset $ — $ —

Organization (Details Narrative

Organization (Details Narrative)	12 Months Ended
	Dec. 31, 2018
State of incorporation	Nevada
Date of incorporation	Jul. 30, 2013
Debride Inc. [Member]
State of incorporation	Florida
Date of incorporation	Oct. 1, 2012

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Allowance for doubtful accounts
Advertising costs	$ 149,000	$ 332,000
Warrant [Member]
Antidilutive securities excluded from computation of earnings per shares	12,108,743	7,402,910
Common Stock [Member]
Antidilutive securities excluded from computation of earnings per shares	557,282	1,314,059
Minimum [Member]
Property plant and equipment useful life	3 years
Maximum [Member]
Property plant and equipment useful life	5 years

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory	$ 131,455	$ 294,714
Split Return Electrodes [Member]
Inventory		1,868
Denervex Device [Member]
Inventory	5,205	111,596
Pro-40 Generator [Member]
Inventory	$ 126,250	$ 181,250

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 23,915	$ 27,100
Loss on asset disposal	$ 32,865

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property and equipment	$ 64,987	$ 135,191
Less accumulated depreciation	(34,594)	(48,018)
Property and Equipment, net	30,393	87,173
Furniture and Fixtures [Member]
Property and equipment	$ 52,857	67,777
Useful Life	5 years
Computers and Software [Member]
Property and equipment	$ 12,130	31,738
Useful Life	3 years
Leasehold Improvements [Member]
Property and equipment		$ 35,676
Useful Life	5 years

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Aug. 08, 2018	Aug. 02, 2018	May 15, 2018	May 01, 2018	Apr. 26, 2018	Mar. 30, 2018	Mar. 26, 2018	Feb. 26, 2018	Jul. 14, 2017	Apr. 21, 2017	Mar. 28, 2017	Feb. 09, 2017	Oct. 14, 2013	Oct. 30, 2018	Sep. 30, 2018	Aug. 31, 2018	Aug. 31, 2017	Aug. 30, 2017	Jan. 31, 2017	Nov. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Oct. 03, 2018	Sep. 28, 2018	Aug. 21, 2018	Aug. 16, 2018	Oct. 28, 2017	Jan. 17, 2017	Nov. 10, 2016
Number of shares issued														320,202		75,000
Shares issued price per share														$ 0.56									$ 0.40			$ 0.32		$ 1.16
Proceeds from issuance of common stock	$ 108,000													$ 180,000							$ 774,502	$ 3,838,671
Consulting expenses																					$ 24,000	115,000
Non vested options outstanding																					88,103
Unrecognized stock-based compensation																					$ 30,000
Weighted average period																					1 year 3 months 11 days
Stock based compensation vested amount																					$ 188,000	$ 544,000
Common stock par value						$ 0.001				$ 0.001	$ 0.001										$ 0.001	$ 0.001
Legal expenses																					$ 13,500
Common stock conversion price, per share	$ 0.40
Proceeds from issuance of warrants																					610,220	$ 1,248,575
Unpaid accrued interest																									$ 100,000
Debt conversion of convertible debt			$ 100,000																			145,919
Debt principal amount																					$ 103,000	$ 104,000
Debt obligations																									$ 2,944
Series B [Member]
Number of warrants issued to purchase common shares			250,000
Beneficial conversion feature of preferred stock			$ 30,000
Debt conversion, shares			1,000
Debt conversion of convertible debt			$ 36,000
Debt obligations			200,000
Short-term Note Payable [Member]
Common stock conversion price, per share												$ 1.04
Short-term note payable												$ 1,150,000
5% Convertible Debenture [Member]
Common stock conversion price, per share					$ 0.38																$ 0.40
Conversion of common stock, percentage					85.00%
Debt conversion, shares					266,301
Unpaid accrued interest					$ 1,194
Debt conversion of convertible debt					$ 100,000
Restricted Common Stock [Member]
Conversion of stock shares converted						1,274,000				525,240	414,663
Series A Preferred Stock [Member]
Conversion of stock shares converted						12,740				5,252	4,147
Series B Convertible Preferred Stock [Member]
Dividend rate		12.00%
Debt conversion of convertible debt			100,000
Common Stock [Member]
Number of common stock shares issued for services																					320,202
Conversion of stock shares converted					266,301																	414,663
Debt conversion, shares																						165,865
Debt conversion of convertible debt																						$ 166
Common Stock [Member] | Short-term Note Payable [Member]
Conversion of stock shares converted												165,865
Warrant [Member]
Warrant, exercise price	0.75																							$ 0.75
Common stock conversion price, per share	0.40
Debt conversion of convertible debt			34,000
Series A Preferred Stock and Warrant [Member] | Short-term Note Payable [Member]
Conversion of stock shares converted												9,399
Promissory Note [Member]
Common stock par value							$ .001
Number of warrants issued to purchase common shares							133,333
Warrant, exercise price							$ 0.75
Debt conversion of convertible debt			200,000
Debt principal amount							$ 200,000														$ 200,000
Debt maturity date							May 15, 2018
Loan balance																					26,000
Unit Purchase Agreement [Member]
Number of shares issued												96,154
Shares issued price per share												$ 1.04
Number of option granted to purchase												100,000
Proceeds from issuance of private placement																					$ 3,022,000
Common stock par value												$ 0.001
Number of warrants issued to purchase common shares												48,077									2,005,761
Warrant, exercise price												$ 1.50
Warrant term												5 years
Unit Purchase Agreement [Member] | Series A Preferred Stock [Member]
Number of shares issued																					12,740
Unit Purchase Agreement [Member] | Common Stock [Member]
Number of shares issued																					1,631,730
Securities Purchase Agreement [Member]
Proceeds from issuance of private placement									$ 2,690,686
Number of warrants issued to purchase common shares									1,478,022
Warrant, exercise price									$ 1.15
Warrant term									5 years
Private placement fees relating to offering									$ 188,000
Number of common stock shares sold, value									$ 2,956,043
Sale of stock price per share									$ 0.91
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Proceeds from issuance of common stock				$ 100,000
Common stock issued percentage															100.00%	100.00%
Proceeds from issuance of private placement								$ 308,000
Common stock par value															$ 0.001	$ 0.001
Number of common stock shares sold								770,000													8.25
Number of warrants issued to purchase common shares								385,000													2,062,500
Warrant, exercise price				$ 0.75				$ 0.75							$ 0.75	$ 0.75
Warrant term				3 years				5 years							3 years	3 years
Number of common stock shares sold, value				$ 1,000,000											$ 1,000,000	$ 1,000,000
Sale of stock price per share															$ 50,000	$ 50,000
Allocation of warrants								52,003
Legal expenses								$ 13,500													$ 5,000
Common stock conversion price, per share															$ 0.40	$ 0.40
Proceeds from issuance of warrants																					825,000
Net cash received from offering																					$ 820,000
Conversion of common stock, percentage															12.00%	12.00%
Purchase price of common stock percentage															90.00%	90.00%
Securities Purchase Agreement [Member] | Investors [Member]
Number of common stock shares sold																					15
Number of warrants issued to purchase common shares																					1,875,000
Number of common stock shares sold, value																					$ 750,000
Common stock conversion price, per share																					$ 0.40
Proceeds from issuance of warrants																					$ 750,000
Debt conversion, shares																					1,875,000
Fair value of warrants																					$ 505,000
Proceeds from notes																					245,000
Accretion expense																					93,000
Unpaid accrued interest																					$ 33,700
Securities Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | Accredited Investors [Member]
Number of shares issued																					159,000
Number of common stock shares sold				1,000																	8,250
Dividend rate				5.00%
Conversion of stock shares converted																					2,062,500
Beneficial conversion feature of preferred stock																					$ 373,000
Unpaid dividends																					$ 58,000
Securities Purchase Agreement [Member] | Common Stock [Member] | Accredited Investors [Member]
Number of warrants issued to purchase common shares				250,000
Warrant, exercise price				$ 0.001
Common stock conversion price, per share				0.40
Market value of common stock				$ 0.44
Securities Purchase Agreement [Member] | Warrant [Member] | Accredited Investors [Member]
Number of warrants issued to purchase common shares																					288,000
May 1, 2018 Securities Purchase Agreement [Member]
Debt conversion of convertible debt			$ 100,000
Maximum [Member] | Warrant [Member]
Warrant, exercise price	$ 0.75																							$ 0.75
Maximum [Member] | Unit Purchase Agreement [Member]
Proceeds from issuance of private placement												$ 5,000,000
Minimum [Member] | Unit Purchase Agreement [Member]
Proceeds from issuance of private placement												3,000,000
2013 Stock Option Incentive Plan [Member]
Stock options authorized incentive plan																											1,000,000		500,000
Compensation expense																					$ 120,000	$ 683,000
2013 Stock Option Incentive Plan [Member] | Maximum [Member]
Shares available for grant																											2,650,000		1,650,000
2013 Stock Option Incentive Plan [Member] | Minimum [Member]
Shares available for grant																											1,650,000		1,150,000
Board of Directors [Member]
Number of common stock issued value																				$ 240,000
Number of shares issued																			173,912
Shares issued price per share																			$ 1.38
Number of common stock shares issued for services																		125,000
Common stock issued percentage																		25.00%
Certain Consultant [Member]
Number of common stock shares issued for services																	175,000
Common stock issued percentage																	25.00%
Consultant [Member]
Number of common stock shares issued for services																						50,000
Number of vested options shares														75,000
Jarrett Gorlin [Member]
Number of shares issued														323,810
Shares issued price per share														$ 0.42									$ 0.40
Proceeds from issuance of common stock														$ 136,000
Employees, Consultants, and Directors [Member] | 2013 Stock Option Incentive Plan [Member] | Maximum [Member]
Plan option grant													1,150,000
Employees [Member] | 2013 Stock Option Incentive Plan [Member]
Number of option granted to purchase																						189,159
Percentage for option vested																						25.00%
Percentage for option vested, description																						The options vest as follows: 25% on the date of grant and 25% on each of the next three anniversaries.
Placement Agent [Member] | Unit Purchase Agreement [Member]
Number of warrants issued to purchase common shares																					405,577
Warrant, exercise price																					$ 1.50
Private placement fees relating to offering																					$ 350,000
Noteholders [Member] | Short-term Note Payable [Member]
Number of common stock issued value												$ 208,000
Number of shares issued												200,000
Shares issued price per share												$ 1.04
Number of warrants issued to purchase common shares												20,000
Number of warrant were cancelled												200,000

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Number Of Shares Options Outstanding Beginning Balance	1,314,059	1,124,900
Number Of Options Granted		189,159
Number Of Options Exercised
Number Of Options Cancelled	(756,777)
Number Of Shares Options Outstanding Ending Balance	557,282	1,314,059
Number Of Shares Options Exercisable	469,179
Weighted Average Exercise Price Outstanding Beginning Balance	$ 2.01	$ 2.15
Weighted Average Exercise Price Granted		1.17
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Cancelled	1.44
Weighted Average Exercise Price Outstanding Ending Balance	2.78	$ 2.01
Weighted Average Exercise Price Exercisable	$ 3.08
Weighted Average Remaining Term (years) Outstanding, Beginning	8 years 2 months 8 days	9 years
Weighted Average Remaining Term (years) Outstanding, Granted		9 years 1 month 6 days
Weighted Average Remaining Term (years) Outstanding, Ending	6 years 11 months 26 days	8 years 2 months 8 days
Weighted Average Remaining Term (years) Exercisable	6 years 10 months 3 days

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative)

Sep. 02, 2018USD ($)

Sep. 02, 2018EUR (€)

Jan. 02, 2018USD ($)

Feb. 01, 2013shares

Oct. 30, 2018shares

Aug. 31, 2018shares

Jan. 31, 2018USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2013

Dec. 31, 2018USD ($)

Dec. 31, 2018EUR (€)

Dec. 31, 2017USD ($)

Accounts payable

$ 37,377

Lease expense

35,000

Accounts payable

750,958

196,171

Number of common stock shares issued | shares

320,202

75,000

TAG Aviation LLC [Member]

Base rent

35,000

34,600

Accounts payable

6,300

Streamline Inc. [Member]

Proceeds from sale of assets

$ 500,000

Contingent description

The terms of the sale also required that for each of the calendar years ending December 31, 2018 and December 31, 2019 (each such calendar year, a "Contingent Period"), a contingent payment in cash (each, a "Contingent Payment") equal to five percent (5%) of the total net sales received by the acquiring party from the sale of "IV suspension system" products in excess of 100 units during each Contingent Period.

Contingent payments

$ 850,000

Streamline Inc. [Member] | Notes Receivable [Member]

Proceeds from sale of assets

$ 150,000

Sales, Marketing, and Distribution Consultant One [Member]

Payments for consulting services

263,000

238,000

Old Lease Agreement [Member]

Base rent

2,948

New Lease Agreement [Member]

Base rent

3,095

Accounts payable

$ 3,400

Agreement, term

2 years 4 months

2 years 4 months

Lease expense

$ 33,000

Non-cancellable 36 Month Operating Lease Agreement [Member]

Lease expense

2,500

2,600

Consulting Agreement [Member]

Consulting fees

13,333

Payments for consulting services

160,000

110,000

Accounts payable

40,000

Increase in consulting fees

$ 9,167

Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant [Member]

Accounts payable

14,000

Payments for consulting services

77,000

66,000

Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant [Member] | Through December 31, 2018 [Member]

Payments for consulting services

7,000

Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant One [Member]

Payments for consulting services

23,000

Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant One [Member] | EURO [Member]

Payments for consulting services | €

€ 21,000

Generator Development Agreement [Member]

Payment to bovie

441,000

Original amount for pathway development

295,000

Generator Development Agreement [Member] | Pro-40 Electrocautery Generator [Member]

Accounts payable

15,000

Payment to bovie

19,000

33,000

Generator Development Agreement [Member] | Pro-40 Electrocautery Generator [Member] | Maximum [Member]

Payment to bovie

295,000

Distribution Center and Logistic Services Agreement [Member]

Accounts payable

16,000

Monthly fees

$ 7,900

3,500

Total expenses

142,000

75,700

Distribution Center and Logistic Services Agreement [Member] | Maximum [Member]

Monthly fees

8,300

Distribution Center and Logistic Services Agreement [Member] | Minimum [Member]

Monthly fees

2,300

Distribution Center and Logistic Services Agreement [Member] | EURO [Member]

Monthly fees | €

€ 6,900

2,900

Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Maximum [Member]

Monthly fees | €

6,900

Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Minimum [Member]

Monthly fees | €

€ 1,900

Co-Development Agreement [Member]

Agreement, description

In exchange for these services the Company was obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews was listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would have continued to receive a 1% royalty after the 2% royalty expired for the duration of the effectiveness of the Improvement Patent. The co-development agreement expired September 30, 2018.

Royalty expense

13,000

1,000

Patent Assignment and Contribution Agreement [Member] | Scott Haufe [Member]

Agreement, description

This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products.

Royalty expense

8,700

800

Number of common stock shares issued | shares

750,108

Royalty expiration

Sep. 6, 2030

Operating Leases [Member]

Base rent

2,147

$ 34,600

Accounts payable

6,300

Operating Leases [Member] | TAG Aviation LLC [Member]

Base rent

$ 34,555

Commitments & Contingencies - S

Commitments & Contingencies - Schedule of Operating Leases (Details)	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
December 31, 2019	$ 37,510
December 31, 2020	38,635
Total	$ 76,145

Short Term Liabilities (Details

Short Term Liabilities (Details Narrative) - USD ($)	May 01, 2018	Apr. 26, 2018	Feb. 26, 2018	Jan. 31, 2018	Jul. 14, 2017	Sep. 30, 2018	Aug. 31, 2018	Mar. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Aug. 08, 2018
Debt instrument face amount									$ 103,000	$ 104,000
Unpaid accrued interest									70,000	69,000
Proceeds from debt									605,424
Market value of common stock											$ 0.40
Proceeds from warrants									610,220	$ 1,248,575
Common Stock [Member]
Conversion of stock shares converted		266,301								414,663
Number of shares issued on conversion										165,865
5% Convertible Debenture [Member]
Debt instrument interest rate				5.00%
Debt instrument maturity date				Jan. 30, 2019
Proceeds from debt				$ 100,000
Debt conversion percentage				85.00%
Convertible Debenture [Member]
Interest expense									$ 1,200
Market value of common stock									$ 0.40
Promissory Note One [Member]
Debt instrument face amount								$ 135,000
Monthly installment amount								$ 5,700
Debt instrument interest rate								5.00%
Debt instrument maturity date								Aug. 1, 2019
Promissory Note Two [Member]
Debt instrument face amount								$ 125,000
Monthly installment amount								$ 5,700
Debt instrument interest rate								5.00%
Debt instrument maturity date								Aug. 1, 2019
Promissory Note [Member]
Interest expense									$ 3,400	$ 7,000
Finance Agreement [Member]
Insurance premium finance payments due									$ 24,000
Insurance premium finance annual percentage									5.98%
Securities Purchase Agreement [Member]
Number of common stock shares sold, value					$ 2,956,043
Sale of stock price per share					$ 0.91
Warrant term					5 years
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Unpaid accrued interest									$ 33,700
Market value of common stock						$ 0.40	$ 0.40
Number of common stock shares sold, value	$ 1,000,000					$ 1,000,000	$ 1,000,000
Sale of stock price per share						$ 50,000	$ 50,000
Conversion of common stock, percentage						12.00%	12.00%
Warrant term	3 years		5 years			3 years	3 years
Number of units sold			770,000						8.25
Warrants to purchase shares of common stock									1,875,000
Proceeds from warrants									$ 825,000
Securities Purchase Agreement [Member] | Investors [Member]
Market value of common stock									$ 0.40
Number of common stock shares sold, value									$ 750,000
Number of units sold									15
Number of shares issued on conversion									1,875,000
Proceeds from warrants									$ 750,000
Fair value of warrants									505,000
Proceeds from the notes									244,576
Accretion expense									$ 93,000

Short Term Liabilities - Schedu

Short Term Liabilities - Schedule of Future Payments Related to the Promissory Notes (Details)	Dec. 31, 2018USD ($)
Debt Disclosure [Abstract]
December 31, 2019	$ 103,000
Total	$ 103,000

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018		Dec. 31, 2017
Equity [Abstract]
Number Of Shares, Warrants Outstanding Beginning	7,402,910		3,713,542
Number Of Shares, Warrants Issued	4,705,833		3,889,368
Number Of Shares, Warrants Cancelled			(200,000)
Number Of Shares, Warrants Outstanding Ending	12,108,743		7,402,910
Number Of Shares, Warrants Exercisable Ending	12,108,743
Weighted Average Exercise Price Outstanding	$ 1.77		$ 2.19
Weighted Average Exercise Price Warrants Issued		[1],[2]	1.37
Weighted Average Exercise Price Warrants Cancelled			1.625
Weighted Average Exercise Price Outstanding	1.38		$ 1.77
Weighted Average Exercise Price Exercisable	$ 1.38
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	3 years 3 months 19 days		3 years 9 months 18 days
Weighted Average Remaining Contractual Life Warrants Outstanding, Issued	2 years 8 months 12 days		4 years 3 months 19 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	2 years 7 months 6 days		3 years 6 months
Weighted Average Remaining Contractual Life Warrants Exercisable	2 years 7 months 6 days
[1]	Warrants issued with the August 8, 2018 and September 28, 2018 convertible notes have an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrant in the event the Company issues any shares of common stock or common stock equivalents in a private placement of equity or debt securities at which 90% of the issuance price is less than $0.75.
[2]	Warrants issued with the May 2018 private placement and debt conversion had an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrant in the event the Company issues any shares of common stock or common stock equivalents in a private placement of equity or debt securities at a price less than $0.75 per share. On August 8, 2018, the Company completed the issuance of convertible debt at an initial conversion price of $0.40. Accordingly the exercise price on these warrants was adjusted downward to $0.40.

Common Stock Warrants - Summa_2

Common Stock Warrants - Summary of Warrant Activity (Details) (Parenthetical) - $ / shares	Sep. 28, 2018	Aug. 08, 2018	Dec. 31, 2018
Conversion price per share		$ 0.40
Warrant [Member]
Warrant initial exercise price	$ 0.75	0.75
Conversion price per share		0.40
Warrant adjusted downward per share		$ 0.40
Warrant equity percentage	90.00%	90.00%
Maximum [Member] | Warrant [Member]
Warrant initial exercise price	$ 0.75	$ 0.75
May 2018 Private Placement [Member]
Warrant initial exercise price			$ 0.75
May 2018 Private Placement [Member] | Maximum [Member]
Warrant initial exercise price			$ 0.75

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details)	12 Months Ended
	Dec. 31, 2018$ / shares
Private Placement 2/26/18 [Member]
MDVX Stock Price	$ 0.51
Exercise Price of Warrant	0.75
Private Placement 2/26/18 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.20
Private Placement 2/26/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	5 years
Private Placement 2/26/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.60%
Private Placement 2/26/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	55.91%
Short-term Debt 3/26/18 [Member]
MDVX Stock Price	$ 0.53
Exercise Price of Warrant	0.75
Short-term Debt 3/26/18 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.22
Short-term Debt 3/26/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	5 years
Short-term Debt 3/26/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.64%
Short-term Debt 3/26/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	56.57%
Private Placement 5/1/18 [Member]
MDVX Stock Price	$ 0.44
Exercise Price of Warrant		[1]
Private Placement 5/1/18 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.24
Private Placement 5/1/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Private Placement 5/1/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.66%
Private Placement 5/1/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	103.29%
Debt Conversion 5/15/18 [Member]
MDVX Stock Price	$ 0.39
Exercise Price of Warrant		[1]
Debt Conversion 5/15/18 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.20
Debt Conversion 5/15/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Debt Conversion 5/15/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.75%
Debt Conversion 5/15/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	103.32%
Convertible Notes 8/8/2018 [Member]
MDVX Stock Price	$ 0.37
Exercise Price of Warrant		[2]
Convertible Notes 8/8/2018 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.19
Convertible Notes 8/8/2018 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Convertible Notes 8/8/2018 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.68%
Convertible Notes 8/8/2018 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	104.37%
Convertible Notes 9/28/2018 [Member]
MDVX Stock Price	$ 0.40
Exercise Price of Warrant		[2]
Convertible Notes 9/28/2018 [Member] | Measurement Input, Grant Date Fair Value [Member]
Fair value assumptions, measurement input, exercise price	$ 0.21
Convertible Notes 9/28/2018 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Convertible Notes 9/28/2018 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.88%
Convertible Notes 9/28/2018 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	105.07%
[1]	Warrants issued with the May 2018 private placement and debt conversion had an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrant in the event the Company issues any shares of common stock or common stock equivalents in a private placement of equity or debt securities at a price less than $0.75 per share. On August 8, 2018, the Company completed the issuance of convertible debt at an initial conversion price of $0.40. Accordingly the exercise price on these warrants was adjusted downward to $0.40.
[2]	Warrants issued with the August 8, 2018 and September 28, 2018 convertible notes have an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrant in the event the Company issues any shares of common stock or common stock equivalents in a private placement of equity or debt securities at which 90% of the issuance price is less than $0.75.

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory rate - federal	21.00%	21.00%
State taxes, net of federal benefit	4.00%	4.00%
Income tax benefit	25.00%	25.00%
Less valuation allowance	(25.00%)	(25.00%)
Total	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Start-up costs	$ 6,816,896	$ 5,566,520
Share-based compensation	243,848	238,109
Total Deferred Tax Assets	7,060,744	5,804,629
Valuation Allowance	(7,060,744)	(5,804,629)
Net Deferred Tax Asset

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounts payable	$ 37,377
Consulting expenses	24,000	115,000
Jesse Crowne [Member]
Accounts payable	40,000
Consulting expenses	160,000	110,000
TAG Aviation LLC [Member]
Rent expense	35,000	$ 34,600
Accounts payable	6,300
Mr. Gorlin [Member] | TAG Aviation LLC [Member]
Rent expense	$ 2,147

Research and Development (Detai

Research and Development (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Research and Development expenses	$ 204,690	$ 491,076
Accounts payable	37,377
Devicix Prototype Manufacturing Agreement [Member]
Research and Development expenses	101,000	302,000
Accounts payable	69,000	7,000
Denervex Generator Manufacturing Agreement [Member]
Research and Development expenses	19,000	33,000
Accounts payable	15,000
Development fees	295,000
Nortech Manufacturing Agreement [Member]
Research and Development expenses	$ 106,000	146,000
Accounts payable		$ 40,000

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net loss	$ 4,908,644	$ 6,456,477
Aggregate amount of debt	103,000	$ 104,000
Asset Purchase Agreement [Member]
Aggregate amount of debt	5,200,000
January 8, 2019 [Member] | Asset Purchase Agreement [Member]
Aggregate amount of debt	2,000,000
Proceeds from debt	1,800,000
Cancellation of debt	200,000
March 31, 2019 [Member] | Asset Purchase Agreement [Member]
Aggregate amount of debt	$ 7,200,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 08, 2019	May 15, 2018	Oct. 30, 2018	Aug. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Dec. 31, 2018	Aug. 08, 2018	Jul. 14, 2017
Number of shares issued			320,202	75,000
Debt instrument face amount						$ 104,000		$ 103,000
Debt instrument converted value		$ 100,000				$ 145,919
Conversion price per share									$ 0.40
RMS Acquisition Corp [Member]
Number of shares issued					39,772,498
Additional common stock issued					11,152,778
RMS Acquisition Corp [Member] | Series C Preferred Stock [Member]
Conversion of stock, shares					39,772
Asset Purchase Agreement [Member]
Debt instrument face amount								$ 5,200,000
Securities Purchase Agreement [Member]
Warrant, exercise price										$ 1.15
Warrant term										5 years
Subsequent Event [Member] | Asset Purchase Agreement [Member] | RMS Acquisition Corp [Member] | Series C Preferred Stock [Member] | Minimum [Member]
Number of shares issued	30,119
Subsequent Event [Member] | Asset Purchase Agreement [Member] | RMS Acquisition Corp [Member] | Series C Preferred Stock [Member] | Maximum [Member]
Number of shares issued	39,772
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Debt instrument face amount							$ 7,200,000
Number of common stock shares sold	50,000
Proceeds from initially offering	$ 8,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]
Debt instrument face amount	$ 50,000
Debt interest rate	12.00%
Debt maturity term	1 year
Conversion price per share	$ 0.40
Percentage for common stock outstanding	4.99%
Penalty interest rate	18.00%
Warrant, exercise price	$ 0.75
Warrant term	3 years
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Four Purchasers [Member]
Debt instrument face amount	$ 2,000,000
Proceeds from debt	1,800,000
Cancellation of debt	$ 200,000
Number of common stock shares sold	40
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Four Purchasers [Member] | Convertible Note [Member]
Debt instrument face amount	$ 50,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Former Chairman [Member]
Number of common stock shares sold	4
Debt instrument converted value	$ 200,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Proceeds from initially offering	1,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Proceeds from initially offering	$ 6,000,000